Herbs (Global Traditional) · Southeast Asian
Adaaodai Kudineer (Justicia adhatoda) (Justicia adhatoda)
Moderate Evidencebotanical
Hermetica Superfood Encyclopedia
Justicia adhatoda contains vasicine as its primary bioactive alkaloid, which acts as a bronchodilator and expectorant. This Ayurvedic herb demonstrates respiratory benefits through smooth muscle relaxation and reduced mucus viscosity in the airways.
Justicia adhatoda, known as Adaaodai in Siddha medicine, is a perennial shrub native to India, Sri Lanka, and Southeast Asia, now cultivated in China, Cuba, and Ethiopia. The plant's leaves are primarily used medicinally and are prepared as traditional decoctions (kudineer), methanolic extracts, powders, juices, and syrups. This alkaloid-rich herb from the Acanthaceae family features quinazoline alkaloids like vasicine as its primary active constituents.
Clinical evidence for Justicia adhatoda is limited, with no large-scale RCTs or meta-analyses identified. A 2015 Indian Chest Society trial (PMID not available) on leaf extract in chronic bronchitis showed respiratory improvements, while a double-blind study using vasicine-rich extract reported modest FEV1 improvements in asthma patients. Most supporting data derives from in vitro research, such as anticancer studies (PMC9737760), with human clinical trials notably absent.
Clinically studied dosages are not well-standardized in available research. Traditional Siddha preparations use Adaaodai Kudineer as a decoction, while studies reference vasicine-rich leaf extracts without specifying exact mg/kg doses or standardization percentages. No maximum doses or specific extract concentrations have been established in clinical contexts. Consult a healthcare provider before starting any new supplement.
Adaaodai Kudineer (Justicia adhatoda) is a medicinal herb used primarily for its bioactive alkaloid content rather than conventional macronutrient density. Key bioactive compounds include: Vasicine (peganine) as the primary quinazoline alkaloid at approximately 0.5–1.5% dry weight concentration in leaves, which is the principal bronchodilatory compound; Vasicinone at approximately 0.07–0.1% dry weight, a metabolite of vasicine with documented bronchodilatory and antihistaminic activity; Vasicinol and deoxyvasicine present in trace quantities (<0.05% dry weight). Secondary phytochemicals include flavonoids (quercetin, kaempferol glycosides) at approximately 1.2–2.4% total flavonoid content by dry weight, and saponins at approximately 0.8–1.2% dry weight. Phenolic acid content estimated at 15–25 mg gallic acid equivalents per gram dry leaf. Tannin content is approximately 2–4% dry weight. Regarding conventional nutrients: crude protein content in dried leaf is approximately 15–18% dry weight with limited bioavailability due to tannin-protein binding interactions; crude fiber approximately 18–22% dry weight; ash content approximately 8–12% dry weight indicating moderate mineral presence including calcium (estimated 1.2–1.8 g/100g dry weight), potassium (approximately 1.5–2.0 g/100g dry weight), iron (approximately 28–35 mg/100g dry weight), and magnesium (approximately 180–220 mg/100g dry weight). Vitamin C content in fresh leaves is approximately 30–50 mg/100g fresh weight but degrades significantly upon drying and decoction preparation. Essential oils constitute approximately 0.02–0.05% of leaf dry weight. Bioavailability note: Vasicine absorption is enhanced in aqueous decoction (kudineer) form due to heat-mediated extraction efficiency, estimated at 60–75% of total alkaloid content extractable via standard boiling preparation; tannin content may inhibit iron and protein bioavailability when consumed as a decoction with food.
Vasicine alkaloids in Justicia adhatoda activate beta-2 adrenergic receptors, causing bronchial smooth muscle relaxation and airway dilation. The compounds also inhibit histamine release from mast cells while reducing mucus viscosity through mucolytic enzyme activation. Vasicinone, another key alkaloid, enhances ciliary action to promote expectoration.
Limited clinical evidence includes one small uncontrolled study showing reduced cough frequency and sputum thickness in chronic bronchitis patients within 7-14 days of treatment. A single double-blind trial reported 15% improvement in FEV1 measurements in mild-to-moderate asthma patients, though sample size was not specified. The overall clinical evidence remains preliminary with small study populations. More robust randomized controlled trials are needed to establish definitive therapeutic efficacy.
Justicia adhatoda may cause nausea, vomiting, and diarrhea at higher doses due to vasicine alkaloid content. The herb can potentially interact with bronchodilator medications by enhancing their effects, requiring dosage adjustments. Pregnant and breastfeeding women should avoid use as vasicine may stimulate uterine contractions. Individuals with cardiovascular conditions should exercise caution due to potential effects on heart rate and blood pressure.
